Brumm Joshua T 4

4 · CRESCENT BIOPHARMA, INC. · Filed Jun 23, 2026

AI-generated summary of this filing

Updated Jun 23, 2026

Crescent Biopharma (CBIO) CEO Joshua Brumm Sells 42,305 Shares

What Happened

Joshua T. Brumm, CEO of Crescent Biopharma (CBIO), reported the sale of 42,305 shares on 2026-06-22. The shares were disposed at a weighted average price of $17.99 for total proceeds of $761,067. This was a sale (not a purchase) and was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.

Key Details

Transaction date: 2026-06-22 (reported on Form 4 filed 2026-06-23).
Transaction type/code: Sale (S).
Shares sold: 42,305; weighted average price: $17.99; price range: $16.88–$18.86.
Total proceeds: $761,067.
Footnotes: Sales were automatic to cover tax withholding for RSUs granted on Dec 15, 2025 and Mar 17, 2025; executed pursuant to a Rule 10b5-1 plan adopted Feb 28, 2026 (stated purpose: cover taxes). The filer can provide per-price breakdowns on request.
Shares owned after transaction: Not disclosed in the provided filing.

Context

These sales were described as routine tax-withholding transactions tied to vested RSUs and executed under a pre-established 10b5-1 plan, which typically indicate administrative need rather than an immediate signal of the insider’s view on the stock. The filing was submitted the day after the transaction, indicating timely reporting.

Form 4

Period: 2026-06-22

DirectorChief Executive Officer

Transactions

Footnotes (2)

[F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Signature

/s/ Barbara Bispham, as attorney-in-fact for Joshua T. Brumm|2026-06-23

1 file